This small-cap pharma stocks engaged in the manufacturing of pharmaceutical products, especially in formulation and API activity. The stocks have jumped up to 6.58 percent following the approval of the merger and acquisition.
Stock movement:
In Tuesday’s trading session, Gujarat Themis Biosyn Limited‘s share surged by 6.58 percent from the previous close of Rs. 304.80. The stock opened at Rs. 313 and is currently trading at Rs. 324.85 with a high of Rs. 339.90 and a low of Rs. 312. The market capitalization now stands at approximately Rs. 3,533.20 crore
Themis Medicare Limited’s share is rising nearly around 2.46 percent from its previous day’s close price of Rs. 286.20. The stock is currently trading at Rs 293.25 per equity share with a market capitalization of Rs. 2,699.08 crore.
What Happened
The boards of Gujarat Themis Biosyn Limited (GTBL) and Themis Medicare Limited (TML) have approved their merger scheme, pending various regulatory approvals. The amalgamation aims to consolidate businesses and integrate the product value chain under a single entity for improved synergies.
According to valuation reports, Themis Medicare Limited will issue 118 equity shares of Rs. 1 each for every 100 shares of face value of Rs. 1 each held in Gujarat Themis Biosyn Limited, as confirmed by merchant banker KJMC Corporate Advisors.
Strategic Expansion of Gujarat Themis Biosyn
Gujarat Themis Biosyn Limited’s expansion strategy focuses on five key areas, which include R&D development with a new unit for intermediate molecules, forward integration into API production, enhanced fermentation capacity, geographical expansion in strategic Indian locations, and infrastructure development compliant with regulatory standards. The company aims to strengthen both domestic and export markets while exploring opportunities in specialty chemicals.
Strategic Expansion of Themis Medicare
Themis Medicare Limited notices significant potential in the hospital business segment, leveraging its strong position in critical care. Despite high entry barriers requiring extensive product portfolios and relationship building, the company aims to achieve leadership in India’s fragmented hospital market, particularly focusing on corporate hospitals and nursing homes through its expertise in complex injectables.
Also read….
Financial results of Gujarat Themis Biosyn
Gujarat Themis Biosyn Limited’s revenue has increased from Rs. 148 crore in FY23 to Rs. 170 crore in FY24, which has grown by 14.86 percent YOY. The net profit of Gujarat Themis Biosyn Limited has also grown by 1.72 percent, from Rs. 58 crore in FY23 to Rs. 59 crore in FY24.
Gujarat Themis Biosyn Limited’s revenue and net profit have grown at a CAGR of 31.90 percent and 57.96 percent, respectively, over the last five years.
Financial results of Themis Medicare
Themis Medicare Limited demonstrated revenue growth from Rs. 354 crore to Rs. 382 crore during FY24, reflecting a 7.91% year-over-year increase. However, the company experienced a decline in net profit, which decreased by 22.81% from Rs. 57 crore in FY23 to Rs. 44 crore in Q2 FY24.
Over the past four years, Themis Medicare Limited has maintained consistent growth, achieving a compound annual growth rate (CAGR) of 17.27% in revenue and 15.18% in net profit.
Company Overview of Gujarat Themis Biosyn
Gujarat Themis Biosyn Limited was established in 1981. Gujarat Themis Biosyn Limited (GTBL) is an Indian pharmaceutical company primarily involved in the manufacturing of pharmaceuticals and medicinal chemical products. The company specializes in the production of active pharmaceutical ingredients (APIs) through fermentation processes.
Company Overview of Themis Medicare
Themis Medicare Limited is an established Indian pharmaceutical company, incorporated on May 31, 1969. The company operates primarily in the research and manufacturing of pharmaceutical products, focusing on formulations and active pharmaceutical ingredients (APIs).
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
Start Your Stock Market Journey Today!
Want to learn Stock Market trading and Investing? Make sure to check out exclusive Stock Market courses by FinGrad, the learning initiative by Trade Brains. You can enroll in FREE courses and webinars available on FinGrad today and get ahead in your trading career. Join now!!
